A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 — Stella

Recruiting

Back to Parkinson Disease Psychosis trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

South Korea

Seoul National University, Seoul

Key details

Phase

Early testing

Sponsor

1ST Biotherapeutics, Inc.

Enrollment target

~64 participants

Started

December 2023

Primary completion

December 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

19 Years and older

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov